pharma · Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation · Myelodysplastic Syndrome · PMVP
PMV Pharmaceuticals
PMV Pharmaceuticals patent portfolio — 11 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- PRINCETON, NJ, USA
- Employees
- 4
- Programs
- 6
- Drugs
- 5
- Patents
- 11
PMV Pharmaceuticals patents
11 pharmaceutical patents indexed for PMV Pharmaceuticals. 0 expire within 24 months.
PMV Pharmaceuticals has 11 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12428406
Methods and compounds for restoring mutant p53 function
granted -
US 12419880
Companion diagnostic tool for mutant p53 reactivating compounds
granted -
US 11963953
Deuterated compounds for restoring mutant p53 function
granted -
US 11938124
Combination therapy for treatment of cancer
granted -
US 11926632
Methods and compounds for restoring mutant p53 function
granted -
US 11814373
Methods and compounds for restoring mutant p53 function
granted -
US 11807644
Methods and compounds for restoring mutant p53 function
granted -
US 11731953
Methods and compounds for restoring mutant p53 function
granted -
US 11339141
Methods and compounds for restoring mutant p53 function
granted -
US 10640485
Methods and compounds for restoring mutant p53 function
granted -
US 10138219
Methods and compounds for restoring mutant p53 function
granted
Frequently asked questions
How many patents does PMV Pharmaceuticals have?
11 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do PMV Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.